Platelet hyperactivity in vitro is found in @entity1 with @entity1007 . It is, however, less well established if platelet activity in vivo is enhanced, and if there are differences between various types of @entity5522 . Platelet function in vivo was studied at rest and during mental stress in @entity1 with @entity1007 (phenotype IIa; n = 21) or @entity5703 (phenotype IIb; n = 29), and age-matched normolipidemic controls (n = 41). The urinary excretion of @entity42338 was elevated in @entity1 compared to controls (IIa, p <0.05; IIb, p <0.001), and higher in type IIb than in IIa @entity1 (p <0.05). Platelet secretion, assessed as plasma @entity4938 levels, was higher in type IIb @entity1 compared to controls (p <0.01) and type IIa @entity1 (p <0.05) during mental stress. The urinary excretion of @entity4938 was also elevated in type IIb @entity1 compared to controls (p <0.05). Platelet aggregability at rest, as measured by filtragometry ex vivo was, however, reduced in both @entity1 groups compared to controls (p <0.05). No correlations were found between plasma lipoprotein levels and markers of platelet function in vivo. Type IIb @entity1 had higher plasma @entity2002 levels and higher leukocyte counts than controls (p <0.05 and p <0.001) and type IIa @entity1 (p <0.05 and p = 0.06). @entity2871 excretion was positively related to @entity2002 levels and leukocyte counts (p <0.01 for both). Preliminary data regarding serum @entity310 also indicated an elevation of this inflammatory cytokine in type IIb @entity1 (p <0.05 vs controls). In conclusion, @entity2871 generation and platelet secretion in vivo are enhanced in @entity1 with @entity1007 , and particularly so among @entity1 with concomitant elevation of plasma @entity1674 . The mechanism is unknown, but inflammatory mediators may be involved. The present findings are of interest in relation to the role of @entity1674 in @entity453 .

Platelet activity in vivo in @entity5522 --importance of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'men'] @entity5703 :: ('MESH:D006950', 'Disease') :: ['combined hyperlipidemia'] @entity2002 :: ('2244', 'Gene') :: ['fibrinogen'] @entity2871 :: ('CHEBI:26995', 'Chemical') :: ['Thromboxane', 'thromboxane'] @entity1007 :: ('MESH:D006937', 'Disease') :: ['isolated hypercholesterolemia', 'hypercholesterolemia'] @entity310 :: ('7124', 'Gene') :: ['TNF-alpha'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity5522 :: ('MESH:D006951', 'Disease') :: ['hyperlipoproteinemia'] @entity42338 :: ('MESH:C049235', 'Chemical') :: ['11-dehydrothromboxane B2'] @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease'] @entity4938 :: ('5473', 'Gene') :: ['beta-thromboglobulin']
@entity5703 :: (MESH:D006950,Disease) :: ['combined hyperlipidemia']
